July 13, 2011 -- Source BioScience (LSE: SBS), the international diagnostics and genetic analysis business, is pleased to announce that the National Health Service Cancer Screening Programmes (“NHSCSP”) has approved the use of the BD FocalPoint “No Further Review” technology for cervical cancer screening in the UK. This is the only automated cervical screening technology which has been approved.
The “No Further Review” technology can analyse and identify up to 25% of screening samples that can be reported as “all clear”, requiring no human examination. With over 3.6 million tests being undertaken across England and Wales during 2009/10, this represents a significant reduction in laboratory workload, eliminating the need to employ costly, temporary locum staff.
NHSCSP, the governing body for cancer screening in the UK, informed NHS laboratories of the decision to approve BD FocalPoint “No Further Review” following recommendations from the Health Technology Assessment “MAVARIC” trial, which was published in March 2011. The trial demonstrated the clinical performance of the system compared with manual screening and its compatibility with the planned introduction of HPV testing into the UK cervical cancer screening programme during September 2011.
Dr Mina Desai, CBE, Head of Cytopathology Services at Manchester Royal Infirmary said “As one of the lead investigators of the MAVARIC study, I am pleased that the “No Further Review” category has been approved. The clinical data from the study supports the decisions to implement it within the screening programme and will assist the laboratories in meeting the demands of the 14 day turnaround time.”
Dr Nick Ash, Chief Executive of Source BioScience commented “We believe BD FocalPoint is a huge step forward for cervical cancer screening progression in the UK. “No Further Review” is a unique function of the BD FocalPoint system and it is the only automated system of its kind approved and available in the UK. Source BioScience will now be able to provide a complete solution for cervical cancer screening from sample collection, processing, imaging and diagnostic testing, including HPV testing.”
For further information, please contact:
Source BioScience plc
Dr Nick Ash, CEO
Tel: +44 (0)115 973 9010
For investor and media enquiries:
Singer Capital Markets Limited (Financial Advisor and Broker)
Shaun Dobson/Claes Spang
Tel: +44 (0)203 205 7500
College Hill (PR Agency to Source BioScience)
Melanie Toyne Sewell/ Dimithri Wignarajah
Tel: +44 (0)207 457 2020
About Source BioScience:
Source BioScience plc (LSE: SBS) is an international diagnostics and genetic analysis business serving the healthcare and research markets. Its Healthcare operations provide screening and reference laboratory diagnostic testing for cancer and other diseases and additional predictive testing for treatment optimisation for clinicians and patients. The LifeSciences division provides core laboratory research support from conceptualisation to implementation, calling upon a wide range of cutting-edge technology platforms including an online catalogue of biomolecular tools. The PharmaBiotech division offers support for early stage therapeutic development, offering a 'one-stop shop' from tissue pathology, immunohistochemistry, sophisticated image analysis, biomarker determination and assay development to pharmacogenomics including genotyping and gene expression analysis. The Group has its headquarters in Nottingham, UK. Further information about Source BioScience can be found at www.sourcebioscience.com